Rigicon Inc., with its global headquarters in NY, USA, announces that their innovative prosthetic urology portfolio received marketing approval from Australia (Australian Government Department of Health Therapeutic Goods Administration)
Rigicon is globally launching two new artificial urinary sphincter models: ContiClassic ® Artificial Urinary Sphincter and ContiReflex ® Artificial Urinary Sphincter. Rigicon announces that ContiClassic ® Artificial Urinary Sphincter and the ContiReflex ® Artificial urinary Sphincter models have recently received CE Mark Approval and is initially available in all major European markets.
Rigicon,Inc. announces that the U.S. Food and Drug Administration (FDA) has cleared Rigi10™ Malleable Penile Prosthesis for implantation into the corpora cavernosa of the penis for men who are diagnosed with erectile dysfunction. The prosthesis is implanted to provide adequate penile rigidity for sexual intercourse.
Rigi10™ is easy to implant and easy to use.